The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Novel treatment strategies in T-cell lymphomas
Francine Foss, MD, Yale University School of Medicine, New Haven, CT, provides an overview of the current treatment landscape of T-cell lymphomas. Phosphoinositide 3-kinase (PI3K) inhibitors such as duvelisib and tenalisib, which can be combined with romidepsin, as well as Janus kinase (JAK) inhibitors including seralutinib represent promising therapeutic options for patients with T-cell lymphomas. Tipifarnib, a farnesyltransferase inhibitor, as well as selinexor are additional drugs that are potential treatments and Prof. Foss additionally highlights novel combinations such as azacitidine and romidepsin, or azacitidine and CHOP. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
